T-Cell–Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028

彭布罗利珠单抗 医学 临床终点 实体瘤疗效评价标准 肺癌 肿瘤科 克拉斯 临床试验 内科学 免疫疗法 临床研究阶段 癌症 结直肠癌
作者
Patrick A. Ott,Yung‐Jue Bang,Sarina A. Piha‐Paul,Albiruni R. Abdul Razak,Jaafar Bennouna,Jean‐Charles Soria,Hope S. Rugo,Roger B. Cohen,Bert H. O’Neil,Janice M. Mehnert,Juanita Lopez,Toshihiko Doi,Emilie M.J. van Brummelen,Răzvan Cristescu,Ping Yang,Kenneth Emancipator,Karen Stein,Mark Ayers,Andrew K. Joe,Jared Lunceford
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:37 (4): 318-327 被引量:985
标识
DOI:10.1200/jco.2018.78.2276
摘要

PURPOSE: Biomarkers that can predict response to anti-programmed cell death 1 (PD-1) therapy across multiple tumor types include a T-cell-inflamed gene-expression profile (GEP), programmed death ligand 1 (PD-L1) expression, and tumor mutational burden (TMB). Associations between these biomarkers and the clinical efficacy of pembrolizumab were evaluated in a clinical trial that encompassed 20 cohorts of patients with advanced solid tumors. METHODS: KEYNOTE-028 ( ClinicalTrials.gov identifier: NCT02054806) is a nonrandomized, phase Ib trial that enrolled 475 patients with PD-L1-positive advanced solid tumors who were treated with pembrolizumab 10 mg/kg every 2 weeks for 2 years or until confirmed disease progression or unacceptable toxicity occurred. The primary end point was objective response rate (ORR; by RECIST v1.1, investigator review). Secondary end points included safety, progression-free survival (PFS), and overall survival (OS). Relationships between T-cell-inflamed GEP, PD-L1 expression, and TMB and antitumor activity were exploratory end points. RESULTS: ORRs (with 95% CIs) ranged from 0% (0.0% to 14.2%) in pancreatic cancer to 33% (15.6% to 55.3%) in small-cell lung cancer. Across cohorts, median (95% CI) PFS ranged from 1.7 months (1.5 to 2.9 months) to 6.8 months (1.9 to 14.1 months) in pancreatic and thyroid cancers, respectively, and median OS from 3.9 months (2.8 to 5.5 months) to 21.1 months (9.1 to 22.4 months) in vulvar and carcinoid tumors, respectively. Higher response rates and longer PFS were demonstrated in tumors with higher T-cell-inflamed GEP, PD-L1 expression, and/or TMB. Correlations of TMB with GEP and PD-L1 were low. Response patterns indicate that patients with tumors that had high levels of both TMB and inflammatory markers (GEP or PD-L1) represent a population with the highest likelihood of response. Safety was similar and consistent with prior pembrolizumab reports. CONCLUSION: A T-cell--inflamed GEP, PD-L1 expression, and TMB predicted response to pembrolizumab in multiple tumor types. These biomarkers (alone/in combination) may help identify patients who have a higher likelihood of response to anti-PD-1 therapies across a broad spectrum of cancers.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
科研老兵完成签到,获得积分10
2秒前
小二郎的应助被陈烨采纳,获得10
4秒前
meta完成签到,获得积分10
7秒前
shaw完成签到,获得积分10
7秒前
hebnkygzs完成签到 ,获得积分10
7秒前
懵懂的莺完成签到,获得积分10
8秒前
ljj完成签到,获得积分10
9秒前
10秒前
碧蓝丹烟完成签到,获得积分10
10秒前
jklling完成签到 ,获得积分10
11秒前
爱吃麦当劳完成签到 ,获得积分10
11秒前
william完成签到,获得积分10
16秒前
神奇蜥蜴完成签到,获得积分10
16秒前
hugefrog完成签到,获得积分10
18秒前
充电宝的应助被aa121599采纳,获得10
18秒前
木又权完成签到,获得积分10
19秒前
白熊爱吃冰淇淋完成签到 ,获得积分10
20秒前
神奇蜥蜴发布了新的文献求助10
22秒前
点点完成签到 ,获得积分10
23秒前
李昕蓥完成签到 ,获得积分10
23秒前
Tqun完成签到,获得积分10
23秒前
研究啥完成签到,获得积分10
26秒前
企鹅完成签到 ,获得积分10
28秒前
小yang完成签到 ,获得积分10
29秒前
阳光雅蕊完成签到,获得积分10
31秒前
小脚丫完成签到 ,获得积分10
31秒前
pyp完成签到,获得积分10
31秒前
32秒前
沉静的清涟完成签到,获得积分10
32秒前
科研通AI65的应助被神奇蜥蜴采纳,获得10
35秒前
萍bao完成签到,获得积分10
36秒前
无言完成签到 ,获得积分10
37秒前
柒柒大王发布了新的文献求助10
37秒前
特特特特特完成签到,获得积分10
38秒前
41秒前
拼搏愚志完成签到,获得积分10
42秒前
竹舍翁暮雨君完成签到 ,获得积分10
42秒前
alex的应助被研究啥采纳,获得10
42秒前
勤奋的猫咪完成签到 ,获得积分10
42秒前
gby完成签到 ,获得积分10
47秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8185537
求助须知:如何正确求助?哪些是违规求助? 9574270
关于积分的说明 21834871
捐赠科研通 7783247
什么是DOI,文献DOI怎么找? 3434577
关于科研通互助平台的介绍 2558951
邀请新用户注册赠送积分活动 2481370